PetrubAI

Executive Summary

PerturbAI is a San Francisco-based biotechnology company pioneering a platform that integrates scalable in vivo CRISPR perturbations with artificial intelligence to systematically map gene function in living organisms. By generating organism-scale perturbation atlases, the company trains AI models to predict how genes and drugs influence biological systems, enabling causal understanding of genetics. This approach aims to accelerate drug discovery by identifying novel therapeutic targets and mechanisms. Founded in 2021, PerturbAI operates at the intersection of functional genomics and machine learning, addressing a critical bottleneck in translating genetic insights into therapies. The company's technology has broad applications in oncology, neurology, and other complex diseases, offering a data-driven method to deconvolute disease biology.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement70% success
• Q1 2027Pharmaceutical Partnership for Target Validation60% success
• Q2 2027Publication of First Organism-Scale Perturbation Atlas80% success